RT Journal Article
SR Electronic
T1 Changes in SARS-CoV-2 Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.14.20153536
DO 10.1101/2020.07.14.20153536
A1 Fenwick, Craig
A1 Croxatto, Antony
A1 Coste, Alix T.
A1 Pojer, Florence
A1 André, Cyril
A1 Pellaton, Céline
A1 Farina, Alex
A1 Campos, Jérémy
A1 Hacker, David
A1 Lau, Kelvin
A1 Bosch, Berend-Jan
A1 Nussle, Semira Gonseth
A1 Bochud, Murielle
A1 D’Acremont, Valerie
A1 Trono, Didier
A1 Greub, Gilbert
A1 Pantaleo, Giuseppe
YR 2020
UL http://medrxiv.org/content/early/2020/07/18/2020.07.14.20153536.abstract
AB We have determined SARS-CoV-2-specific antibody responses in a cohort of 96 individuals with acute infection and in 578 individuals enrolled in a seroprevalence population study in Switzerland including three groups, i.e. subjects with previous RT-PCR confirmed SARS-CoV-2 infections (n=90), ‘positive patient contacts’ (n=177) and ‘random selected subjects’ (n=311). SARS-CoV-2 antibody responses specific to the Spike (S), in the monomeric and native trimeric forms, and/or the nucleocapsid (N) proteins were equally sensitive in the acute infection phase. Interestingly, as compared to anti-S antibody responses, those against the N protein appear to wane in the post-infection and substantially underestimated the proportion of SARS-CoV-2 infections in the groups of ‘patient positive contacts’, i.e. 10.9 to 32.2% reduction and in the ‘random selected’ general population, i.e. up to 45% reduction. The overall reduction in seroprevalence targeting only anti-N IgG antibodies for the total cohort ranged from 9.4 to 31%. Of note, the use of the S protein in its native trimer form was more sensitive as compared to monomeric S proteins.These results indicate that the assessment of anti-S IgG antibody responses against the native trimeric S protein should be implemented to estimate SARS-CoV-2 infections in population-based seroprevalence studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this project was provided through the Lausanne University Hospital, through the Swiss Vaccine research institute and through the Coronavirus Accelerated R&D in Europe (CARE) IMI project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Commission ethique du Canton de Vaud (CER-VD) stated that authorization was not requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request